financetom
Business
financetom
/
Business
/
Dollar Tree Fiscal Q1 Adjusted Earnings, Revenue Rise; Full-Year Adjusted EPS Outlook Updated
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Dollar Tree Fiscal Q1 Adjusted Earnings, Revenue Rise; Full-Year Adjusted EPS Outlook Updated
Jun 4, 2025 4:32 AM

07:07 AM EDT, 06/04/2025 (MT Newswires) -- Dollar Tree ( DLTR ) reported fiscal Q1 adjusted earnings from continuing operations Wednesday of $1.26 per diluted share, up from $1.23 a year earlier.

Analysts polled by FactSet expected $1.21.

Revenue for the quarter ended May 3 was $4.64 billion compared with $4.17 billion a year earlier.

Analysts surveyed by FactSet expected $4.54 billion.

The company said it expects its fiscal Q2 adjusted EPS from continuing operations to be down as much as 45% to 50% year-over-year before re-accelerating in the next two quarters to meet its full-year outlook.

For fiscal 2025, Dollar Tree ( DLTR ) said it now expects adjusted EPS from continuing operations of $5.15 to $5.65, compared with its previous outlook range of $5 to $5.50. The company maintained its annual sales guidance of $18.5 billion to $19.1 billion.

Analysts polled by FactSet expect adjusted EPS of $5.28 on sales of $19.58 billion.

Dollar Tree ( DLTR ) shares were down 3.6% in recent premarket activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Update: Lexeo Shares Tumble Despite 'Positive' Data in Trials of Gene Therapy Candidate for Cardiac Disorder
Update: Lexeo Shares Tumble Despite 'Positive' Data in Trials of Gene Therapy Candidate for Cardiac Disorder
Jul 15, 2024
12:50 PM EDT, 07/15/2024 (MT Newswires) -- (Updated with share price movement in the headline and first paragraph) Lexeo Therapeutics ( LXEO ) shares sank more than 29% in recent Monday trading despite positive interim data from phase 1/2 trials of its experimental gene therapy, LX2006, to treat Friedreich ataxia cardiomyopathy. Earlier in the day, the company said the trial...
Cinemark Subsidiary Launches Senior Notes Cash Tender Offer; Shares Drop
Cinemark Subsidiary Launches Senior Notes Cash Tender Offer; Shares Drop
Jul 15, 2024
12:50 PM EDT, 07/15/2024 (MT Newswires) -- Cinemark Holdings ( CNK ) said Monday its Cinemark USA unit has launched a cash tender offer to buy all of Cinemark USA's 5.875% senior notes due 2026. The offering will expire at 5 p.m. ET on Monday. Cinemark USA had $405 million worth of outstanding notes as of July 9. Shares of...
Stellantis to Offer At-Home Charging Station or Charge Credits With EV Purchase
Stellantis to Offer At-Home Charging Station or Charge Credits With EV Purchase
Jul 15, 2024
12:50 PM EDT, 07/15/2024 (MT Newswires) -- Stellantis ( STLA ) said Monday it would begin offering customers at-home charging stations or charge credits with the purchase of battery electric vehicles. The company announced the offerings under a program called Free2move Charge which would either offer customers a level 2 charging unit at their home or $600 in charging credits...
Why Mira Pharmaceuticals Stock Is Moving Higher Monday
Why Mira Pharmaceuticals Stock Is Moving Higher Monday
Jul 15, 2024
MIRA Pharmaceuticals, Inc. ( MIRA ) shares are trading higher after the company said testing has confirmed its preliminary beliefs regarding a new potential treatment for neurological and neuropsychiatric disorders. The Details: The company is currently evaluating a pharmaceutical drug, MIRA-55, as a possible treatment for anxiety and cognitive decline. Preclinical tests showed promising results including stronger efficacy when compared...
Copyright 2023-2026 - www.financetom.com All Rights Reserved